Clinical Trials Logo

Clinical Trial Summary

Background: fluctuation of cerebral blood flow and oxygenation in neonates who undergo intensive care is an important risk factor for risk of neurodevelopmental impairment. Near infrared spectroscopy (NIRS) allow direct measurements of cerebral tissue oxygenation. Automated Fraction of Inspired Oxygen (FiO2) adjustment can maintain arterial oxygen saturation (SpO2) within a target range and may reduce risk of fluctuation of cerebral oxygenation.

Aim of this study: to evaluate the efficacy of automated FiO2 adjustment in maintaining SpO2 within a target range and in reducing the risk of cerebral tissue hypo-oxygenation due to SpO2 fluctuations in preterm infants on invasive or non invasive respiratory support with supplemental oxygen.


Clinical Trial Description

Background: fluctuation of cerebral blood flow and oxygenation in neonates who undergo intensive care is an important risk factor for risk of neurodevelopmental impairment. Near infrared spectroscopy (NIRS) allow direct measurements of cerebral tissue oxygenation. Automated FiO2 adjustment can maintain arterial oxygen saturation (SpO2) within a target range and may reduce risk of fluctuation of cerebral oxygenation.

Aim of this study: to evaluate the efficacy of automated FiO2 adjustment in maintaining SpO2 within a target range and in reducing the risk of cerebral tissue hypo-oxygenation due to SpO2 fluctuations in preterm infants on invasive or non invasive respiratory support with supplemental oxygen.

Methodology: multicenter randomized cross-over clinical trial. The study will be carried out for almost 1 year .

Study centers: 7 Italian Neonatal Intensive Care Units (NICUs) Number of subjects: 60 infants to have a >90% power, with an alpha of p=0.01, of detecting a 5% difference in %-time in the target range and a 50% difference in both SpO2 hyperoxic and hypoxic %-time.

Diagnosis and main inclusion criteria: preterm infants of 25+0-28+6 weeks of gestational age, requiring invasive or non invasive respiratory support and supplemental oxygen.

Other enrollment requirements: All infants will be enrolled between >72 hours (end of transition period) and </= 7 days. Expected to remain of the current mode of support for the 48-hour intervention period. Infants with major congenital anomalies, haemodynamic instability (patent ductus arteriosus-PDA) or requiring catecholamines treatment, clinical evidence of seizures or ongoing sepsis (positive blood culture) during the study, or within 24 hours prior of enrollment, will be excluded.

Study product:AVEA ventilator with closed-loop inspired oxygen control (CLiO2) automated FiO2 control option. An additional sensor will be attached to the infant's forehead for continuous measurement of cerebral tissue oxygen saturation (rStO2) with 5100C NIRS oximeter, Covidien.

Duration:24 hours each of manual control and CLiO2 control. Reference therapy:Manual control of FiO2 provided according to standardized guidelines.

Statistical Methodology: repeated measures mixed linear model with control from sequence and ventilation mode.

Concurrent safety oversight:Independent Data Safety Monitoring Board, with blinded review every 6 months or 50% enrollment, and after 15 subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02748447
Study type Interventional
Source Ospedale L. Sacco – Polo Universitario
Contact Ilaria Stucchi, MF
Phone 00393358050962
Email stucchi.ilaria@icp.mi.it
Status Recruiting
Phase N/A
Start date April 2016
Completion date July 2017

See also
  Status Clinical Trial Phase
Completed NCT02785926 - Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates
Completed NCT01946971 - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Phase 1/Phase 2
Completed NCT01530360 - Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants Phase 1
Completed NCT00681018 - Feeding Study in Premature Infants N/A
Completed NCT00217191 - Ibuprofen and Renal Function in Premature Infants Phase 4
Completed NCT01077271 - Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA N/A
Completed NCT00282113 - Effects of Probiotic and Prebiotic Combinations on Premature Infants N/A
Active, not recruiting NCT02943746 - Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants N/A
Completed NCT01994954 - A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants N/A
Completed NCT00389909 - Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants Phase 4
Completed NCT00747591 - Urine Concentration of S100B in Extremely Premature Infants N/A
Recruiting NCT04555590 - Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants N/A
Completed NCT06352047 - The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions N/A
Completed NCT03217045 - Nutrition Protocol and Premature Infants' Growth
Recruiting NCT03552952 - Development of Preterm Infant Gut Microbiome
Recruiting NCT06332521 - Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment
Completed NCT04659083 - How NAVA Works in Preterm Infants With Irregular Respiratory Efforts
Completed NCT05807191 - The Effect of Using Clinical Guidelines on Kangaroo Care on Newborn and Maternal Outcomes N/A
Completed NCT03914690 - Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage Phase 2
Completed NCT01140243 - Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital N/A